Ascher-Svanum, H: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

Don't use scam websites

1

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

Douglas Faries, Haya Ascher-Svanum, Baojin Zhu, Christoph Correll, John Kane

Journal:

Year:

2005

Language:

english

File:

PDF, 1.05 MB

english, 2005

2

Erratum to: Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis

Ascher-Svanum, Haya, Zagar, Anthony, Jiang, Dingfeng, Schuster, Dara, Schmitt, Henry, Dennehy, Ellen B., Kendall, David M., Raskin, Joel, Heine, Robert J.

Journal:

Diabetes Therapy

Year:

2015

Language:

english

File:

PDF, 337 KB

english, 2015

3

The cost of relapse and the predictors of relapse in the treatment of schizophrenia

Haya Ascher-Svanum, Baojin Zhu, Douglas E Faries, David Salkever, Eric P Slade, Xiaomei Peng, Robert R Conley

Journal:

Year:

2010

Language:

english

File:

PDF, 215 KB

english, 2010

4

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study

Gebra B Cuyún Carter, Denái R Milton, Haya Ascher-Svanum, Douglas E Faries

Journal:

Year:

2011

Language:

english

File:

PDF, 264 KB

english, 2011

5

Item response analysis of the Positive and Negative Syndrome Scale

Darcy A Santor, Haya Ascher-Svanum, Jean-Pierre Lindenmayer, Robert L Obenchain

Journal:

Year:

2007

Language:

english

File:

PDF, 1.01 MB

english, 2007

6

The Soviet woman in the family and in society: A sociological study: Feiga Blekher Jerusalem: Keter Publishing House, 1979

Haya Ascher-Svanum

Journal:

International Journal of Intercultural Relations

Year:

1980

Language:

english

File:

PDF, 141 KB

english, 1980

7

Updating and Confirming an Industry-Sponsored Pharmacoeconomic Model: Comparing Two Antipsychotics in the Treatment of Schizophrenia

Christopher N. Graham, Josephine A. Mauskopf, Anthony H. Lawson, Haya Ascher-Svanum, David Bruhn

Journal:

Value in Health

Year:

2012

Language:

english

File:

PDF, 1.14 MB

english, 2012

8

Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms

Virginia L. Stauffer, Guochen Song, Bruce J. Kinon, Haya Ascher-Svanum, Lei Chen, Peter D. Feldman, Robert R. Conley

Journal:

Schizophrenia Research

Year:

2012

Language:

english

File:

PDF, 568 KB

english, 2012

9

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

Kinon, Bruce J, Chen, Lei, Ascher-Svanum, Haya, Stauffer, Virginia L, Kollack-Walker, Sara, Zhou, Wei, Kapur, Shitij, Kane, John M

Journal:

Neuropsychopharmacology

Year:

2010

Language:

english

File:

PDF, 473 KB

english, 2010

10

Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis

H. Ascher-svanum, A. Zagar, D. Jiang, D. Schuster, H. Schmitt, E. B. Dennehy, D. M. Kendall, J. Raskin, R. J. Heine

Journal:

Diabetes Therapy

Year:

2015

Language:

english

File:

PDF, 1.01 MB

english, 2015

11

A psychoeducational intervention for schizophrenic patients

Haya Ascher-Svanum

Journal:

Patient Education and Counseling

Year:

1989

Language:

english

File:

PDF, 482 KB

english, 1989

12

A MODEL COMPARING OLANZAPINE AND ZIPRASIDONE IN PATIENTS WITH SCHIZOPHRENIA

I Alexeyeva, J Mauskopf, S Earnshaw, Pj Gibson, H Ascher-Svanum, Jl Ramsey

Journal:

Value in Health

Year:

2001

Language:

english

File:

PDF, 999 KB

english, 2001

13

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

Haya Ascher-Svanum, Allen W Nyhuis, Douglas E Faries, Daniel E Ball, Bruce J Kinon

Journal:

Year:

2010

Language:

english

File:

PDF, 249 KB

english, 2010

14

Predictors of switching antipsychotic medications in the treatment of schizophrenia

Allen W Nyhuis, Douglas E Faries, Haya Ascher-Svanum, Virginia L Stauffer, Bruce J Kinon

Journal:

Year:

2010

Language:

english

File:

PDF, 1.54 MB

english, 2010

15

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

Haya Ascher-Svanum, Fangyi Zhao, Holland C Detke, Allen W Nyhuis, Anthony H Lawson, Virginia L Stauffer, William Montgomery, Michael M Witte, David P McDonnell

Journal:

Year:

2011

Language:

english

File:

PDF, 449 KB

english, 2011

16

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia

Stephen J Ruberg, Lei Chen, Virginia Stauffer, Haya Ascher-Svanum, Sara Kollack-Walker, Robert R Conley, John Kane, Bruce J Kinon

Journal:

Year:

2011

Language:

english

File:

PDF, 443 KB

english, 2011

17

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics

Hong Liu-Seifert, Haya Ascher-Svanum, Olawale Osuntokun, Kai Yu Jen, Juan Carlos Gomez

Journal:

Year:

2011

Language:

english

File:

PDF, 350 KB

english, 2011

18

Cost of antipsychotic polypharmacy in the treatment of schizophrenia

Baojin Zhu, Haya Ascher-Svanum, Douglas E Faries, Christoph U Correll, John M Kane

Journal:

Year:

2008

Language:

english

File:

PDF, 459 KB

english, 2008

19

Costs of treating patients with schizophrenia who have illness-related crisis events

Baojin Zhu, Haya Ascher-Svanum, Douglas E Faries, Xiaomei Peng, David Salkever, Eric P Slade

Journal:

Year:

2008

Language:

english

File:

PDF, 539 KB

english, 2008

20

Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials

Virginia Stauffer, Haya Ascher-Svanum, Lin Liu, Tamara Ball, Robert Conley

Journal:

Year:

2009

Language:

english

File:

PDF, 928 KB

english, 2009

21

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients

Haya Ascher-Svanum, Xiaomei Peng, Douglas Faries, William Montgomery, Peter M Haddad

Journal:

Year:

2009

Language:

english

File:

PDF, 193 KB

english, 2009

22

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

Douglas E Faries, Haya Ascher-Svanum, Allen W Nyhuis, Bruce J Kinon

Journal:

Year:

2009

Language:

english

File:

PDF, 453 KB

english, 2009

23

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration

Lizheng Shi, Haya Ascher-Svanum, Yi-Ju Chiang, Yingnan Zhao, Vivian Fonseca, Daniel Winstead

Journal:

Year:

2009

Language:

english

File:

PDF, 523 KB

english, 2009

24

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia

Haya Ascher-Svanum, Baojin Zhu, Douglas Faries, Frank R Ernst

Journal:

Annals of General Psychiatry

Year:

2004

Language:

english

File:

PDF, 880 KB

english, 2004

25

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

Douglas E Faries, Allen W Nyhuis, Haya Ascher-Svanum

Journal:

Cost Effectiveness and Resource Allocation

Year:

2009

Language:

english

File:

PDF, 219 KB

english, 2009

26

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

Nicolas M Furiak, Haya Ascher-Svanum, Robert W Klein, Lee J Smolen, Anthony H Lawson, Robert R Conley, Steven D Culler

Journal:

Cost Effectiveness and Resource Allocation

Year:

2009

Language:

english

File:

PDF, 2.17 MB

english, 2009

27

Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial

Sandra L. Tunis, Douglas E. Faries, Allen W. Nyhuis, Bruce J. Kinon, Haya Ascher-Svanum, Ralph Aquila

Journal:

Value in Health

Year:

2006

Language:

english

File:

PDF, 155 KB

english, 2006

28

Classifying Patients by Antipsychotic Adherence Patterns Using Latent Class Analysis: Characteristics of Nonadherent Groups in the California Medicaid (Medi-Cal) Program

Jeonghoon Ahn, Jeffrey S. McCombs, Changun Jung, Tim J. Croudace, David McDonnell, Haya Ascher-Svanum, Eric T. Edgell, Lizheng Shi

Journal:

Value in Health

Year:

2008

Language:

english

File:

PDF, 118 KB

english, 2008

29

Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study

A. J. M. Brnabic, K. Kelin, H. Ascher-Svanum, W. Montgomery, Z. Kadziola, J. Karagianis

Journal:

International Journal of Clinical Practice

Year:

2011

Language:

english

File:

PDF, 173 KB

english, 2011

30

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial

Lei Chen, Glenn Phillips, Joseph Johnston, Bruce J Kinon, Haya Ascher-Svanum, Sara Kollack-Walker, Paul Succop, Dieter Naber

Journal:

Year:

2011

Language:

english

File:

PDF, 301 KB

english, 2011

31

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia

Haya Ascher-Svanum, Michael Stensland, Zhongyun Zhao, Bruce J Kinon

Journal:

Year:

2005

Language:

english

File:

PDF, 579 KB

english, 2005

32

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

Haya Ascher-Svanum, Baojin Zhu, Douglas Faries, Ron Landbloom, Marvin Swartz, Jeff Swanson

Journal:

Year:

2006

Language:

english

File:

PDF, 711 KB

english, 2006

33

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia

Haya Ascher-Svanum, Baojin Zhu, Douglas E Faries, Nicolas M Furiak, William Montgomery

Journal:

BMC Research Notes

Year:

2009

Language:

english

File:

PDF, 229 KB

english, 2009

34

Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan

Wenyu Ye, Shinji Fujikoshi, Naohiro Nakahara, Michihiro Takahashi, Haya Ascher-Svanum, Tetsuro Ohmori

Journal:

Psychiatry and Clinical Neurosciences

Year:

2012

Language:

english

File:

PDF, 391 KB

english, 2012

35

Poster Abstract #3: Cognitive Status of Patients With Schizophrenia as Modulator or Mediator of Functional Outcome

Ilya Lipkovich, Sara Kollack-Walker, Bruce Kinon, Virginia Stauffer, Haya Ascher-Svanum, Richard Keefe

Journal:

Neurotherapeutics

Year:

2007

Language:

english

File:

PDF, 46 KB

english, 2007

36

Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis

Virginia L. Stauffer, Michael Case, Bruce J. Kinon, Robert Conley, Haya Ascher-Svanum, Sara Kollack-Walker, John Kane, Joseph McEvoy, Jeffrey Lieberman

Journal:

Psychiatry Research

Year:

2011

Language:

english

File:

PDF, 345 KB

english, 2011

37

Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation

Louis S. Matza, Glenn A. Phillips, Dennis A. Revicki, Haya Ascher-Svanum, Dawn Kaiser, Virginia Stauffer, Jodi M. Shorr, Bruce J. Kinon

Journal:

Psychiatry Research

Year:

2011

Language:

english

File:

PDF, 168 KB

english, 2011

38

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia

Witte, Michael M., Case, Michael G., Schuh, Kory J., Ascher-Svanum, Haya

Journal:

Current Medical Research and Opinion

Year:

2012

Language:

english

File:

PDF, 217 KB

english, 2012

39

Number needed to treat (NNT) for all-cause medication discontinuation in catie compared to the schizophrenia outpatients health outcomes (SOHO) study

D. Novick, D. Suarez, H. Ascher-Svanum, J. Karagianis, E. Perrin, J.M. Haro, J. Alonso, I. Gasquet, J.M. Haro, P.B. Jones, J. Lepine

Journal:

European Psychiatry

Year:

2007

Language:

english

File:

PDF, 44 KB

english, 2007

40

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

H. Ascher-Svanum, X. Peng, W. Montgomery, D.E. Faries, A.H. Lawson, M.M. Witte, D. Novick, N. Jemiai, E. Perrin, D.P. McDonnell

Journal:

European Psychiatry

Year:

2011

Language:

english

File:

PDF, 393 KB

english, 2011

41

Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia

Louis S. Matza, Glenn A. Phillips, Dennis A. Revicki, Haya Ascher-Svanum, Karen G. Malley, Andrew C. Palsgrove, Douglas E. Faries, Virginia Stauffer, Bruce J. Kinon, A. George Awad, Richard S.E. Keefe

Journal:

Psychiatry Research

Year:

2012

Language:

english

File:

PDF, 169 KB

english, 2012

42

P.3.c.040 Antipsychotic effectiveness based on early response in the treatment of schizophrenia

B. Kinon, L. Chen, H. Ascher-Svanum, V. Stauffer, S. Kollack- Walker

Journal:

European Neuropsychopharmacology

Year:

2007

Language:

english

File:

PDF, 67 KB

english, 2007

43

P.3.c.060 Differences in early responders/early non-responders to atypical antipsychotics on functional outcomes in schizophrenia

B. Kinon, L. Chen, V.L. Stauffer, H. Ascher-Svanum, W. Zhou, O. Tomori, S. Kollack-Walker, J.M. Kane, S. Kapur

Journal:

European Neuropsychopharmacology

Year:

2008

Language:

english

File:

PDF, 68 KB

english, 2008

44

S.05.02 Early response as a response predictor: use of individual variability in clinical trials

B.J. Kinon, L. Chen, H. Ascher-Svanum, V. Stauffer, S. Kollack-Walker, W. Zhou, S. Kapur, J. Kane

Journal:

European Neuropsychopharmacology

Year:

2009

Language:

english

File:

PDF, 99 KB

english, 2009

45

P.3.c.011 Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label study

H. Detke, P.J. Weiden, T. Lambert, P.M. Llorca, M. Choukour, S.B. Watson, E. Brunner, H. Ascher-Svanum

Journal:

European Neuropsychopharmacology

Year:

2010

Language:

english

File:

PDF, 44 KB

english, 2010

46

PMH11 MEDICATION USE PATTERNS AND COSTS ASSOCIATED WITH ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF BIPOLAR DISORDER

B Zhu, P Kulkarni, M Stensland, H Ascher-Svanum

Journal:

Value in Health

Year:

2007

Language:

english

File:

PDF, 69 KB

english, 2007

47

PMH38 ASSESSING PERSISTENCE OF ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA: USING THE DATA FROM PENNSYLVANIA MEDICAID TO UNDERSTAND THE CHALLENGES

B Zhu, DE Ball, GA Phillips, D Faries, Z Zhao, H Ascher-Svanum

Journal:

Value in Health

Year:

2007

Language:

english

File:

PDF, 86 KB

english, 2007

48

PMH43 SWITCHING OF ANTIPSYCHOTICS AMONG STABLE AND UNSTABLE SCHIZOPHRENIA PATIENTS

B Zhu, H Ascher-Svanum, B Johnstone, D Faries

Journal:

Value in Health

Year:

2007

Language:

english

File:

PDF, 86 KB

english, 2007

49

PMH17 METABOLIC MONITORING AMONG SCHIZOPHRENIA PATIENTS INITIATED ON ATYPICAL ANTIPSYCHOTICS IN THE VETERAN HEALTH ADMINISTRATION

L Shi, H Ascher-Svanum, YJ Chiang, V Fonseca, D Winstead

Journal:

Value in Health

Year:

2008

Language:

english

File:

PDF, 74 KB

english, 2008

50

PMH8 TREATMENT DURATION FOLLOWING INITIATION ON ATYPICAL ANTIPSYCHOTICS AMONG SCHIZOPHRENIA PATIENTS WITH VERSUS WITHOUT A METABOLIC SYNDROME

L Shi, H Ascher-Svanum, YJ Chiang, V Fonseca, D Winstead

Journal:

Value in Health

Year:

2008

Language:

english

File:

PDF, 68 KB

english, 2008